Wed 2/19/2020 08:05 ET
S&P 5003370.299.770.29%BANKS495.957.791.57%OIL53.020.731.38%BITCOIN10135.4215.200.15%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Aldeyra Therapeutics, Inc - ALDX   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ALDX
From: singhtelecom (Rep: 971)Date: 07/07/2017 08:52
Forum: Aldeyra Therapeutics, Inc - Msg #21Thread #673937218 (Rec: 0)
we are excited to commence Phase 3 clinical testing of our novel aldehyde trap, ADX-102, in noninfectious anterior uveitis," said Todd Brady, M.D., Ph.D., president and CEO. "NAU is a rare and potentially blinding ocular disorder that affects an estimated 150,000 patients in the United States. In contrast to corticosteroids, which are often used to treat NAU, ADX-102 does not appear to cause increases in intraocular pressure -- a precursor to glaucoma -- and thus may represent a safer therapeutic option than the current standard of care." ADX-102 and other product candidates generated from Aldeyra's aldehyde trap platform sequester and facilitate the degradation of aldehydes, a class of endogenously generated pro-inflammatory mediators. In a Phase 2 clinical trial in NAU, 0.5% topical ocular ADX-102 led to the resolution of inflammation to the same degree as corticosteroid therapy, but without the increases in intraocular pressure observed in corticosteroid-treated patients. The Phase 3 clinical trial is expected to enroll up to 100 NAU patients with active disease, randomized equally to receive either 0.5% topical ocular ADX-102 or vehicle for four weeks. Consistent with the Phase 2 trial, the primary endpoint will be the resolution of inflammation. Results of the Phase 3 trial are expected in the second half of 2018.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreALDX: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ALDX | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.